AbbVie's Venetoclax patent bid in India fails after invention ruled obvious  MLex

AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.

AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend. AbbVie (ABBV 0.66%) is an investment that is full of contradictions. It has a strong pharmaceutical business, but the third quarter of 2025 was terrible on the earnings front. It has an attractive 3% dividend yield, but it is near the low side of the historical yield range.

AbbVie’s initiative I Know IBD has been awarded the Bronze at the PR Awards 2025, promoting understanding of inflammatory bowel disease.

AbbVie’s Phase 3 ECLIPSE study shows atogepant’s superiority over placebo in treating acute migraines. Lynk Pharmaceuticals gains FDA IND approval for LNK01006, a TYK2 inhibitor for neuroinflammatory diseases. GEN Pharmaceuticals reports promising Phase 1 data for SUL-238 in Alzheimer’s and neurodegenerative diseases. Johnson & Johnson’s IMAAVY® gains European approval for myasthenia gravis, offering up to 20 months of disease control. Kallyope’s Elismetrep shows positive results for migraine treatment, and Lundbeck’s Bexicaserin offers sustained seizure reduction in rare childhood-onset epilepsies.

AbbVie reveals groundbreaking results from the ECLIPSE study, highlighting atogepant's significant efficacy in acute migraine treatment, aiming to enhance patient care.

AbbVie has shared significant findings from the ECLIPSE study at the European Headache Congress, highlighting Atogepant's effectiveness in treating migraines.

AbbVie unveils Phase 3 ECLIPSE data at the European Headache Congress, showcasing Atogepant's superior efficacy over placebo for acute migraine treatment.

The partnership with Aliada Therapeutics centers on a platform technology designed to ferry large-molecule therapies across the protective blood-brain barrier (BBB) for lysosomal storage disorders (LSDs).

The partnership with Aliada Therapeutics centers on a platform technology designed to ferry large-molecule therapies across the protective blood-brain barrier (BBB) for lysosomal storage disorders (LSDs).

Skyrizi and Rinvoq sales are pushing AbbVie's sales higher.

Skyrizi and Rinvoq sales are pushing AbbVie's sales higher.

Skyrizi and Rinvoq sales are pushing AbbVie's sales higher.

Healthcare stocks in the S&P 500 offer an average dividend yield of 1.8%.

AbbVie has revealed its financial results for Q3 2025, noting significant changes in earnings. This article examines the figures and the company's outlook.

AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a head-to-head .